Weekly Tirzepatide Use May Lead to Weight Loss Over 3 Years in Non-Diabetic Adults
Click to start listening
Synopsis
New Delhi, April 13 (NationPress) A weekly regimen of tirzepatide may facilitate clinically significant weight loss for at least 3 years in adults who are overweight or obese without diabetes, according to recent findings presented at the European Congress on Obesity.
Key Takeaways
- Tirzepatide can produce sustained weight loss for up to 3 years.
- Women and individuals without obesity-related complications respond better.
- No new safety issues were reported, with common side effects including nausea and diarrhea.
- Personalized treatment strategies may be developed based on demographic insights.
- The drug mimics natural hormones to regulate appetite and insulin secretion.
New Delhi, April 13 (NationPress) A recent study reveals that taking tirzepatide once a week can result in clinically significant and sustained weight loss for a minimum of 3 years in adults who are overweight or obese without diabetes. This research was presented at the European Congress on Obesity (ECO) in Malaga, Spain.
The research team, led by Dr. Luca Busetto from the University of Padova in Italy, along with colleagues from Eli Lilly and Company, noted that women and individuals without obesity-related complications may exhibit a better response to tirzepatide treatment.
This study is an extension of the SURMOUNT-1 phase 3 trial, which assessed tirzepatide, a medication approved in both the EU and USA for managing obesity and type 2 diabetes.
No new safety concerns were identified during the trial; the most frequently reported side effects included nausea, diarrhea, and constipation.
According to Busetto, “Our long-term evaluation of tirzepatide demonstrates that clinically significant weight loss can be maintained for up to 3 years among a varied cohort of adults who are overweight or obese but do not have diabetes, irrespective of age, BMI, and obesity duration at the beginning of the study.”
However, not all individuals respond to the medication equally, and a higher likelihood of successful weight loss was observed in groups with a greater percentage of women and those free of obesity-related medical conditions, Busetto added.
Tirzepatide operates by mimicking the hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are naturally released by the gut after eating, stimulating insulin release.
It also curbs appetite by prolonging gastric emptying and interacts with brain areas containing GLP-1 receptors to convey feelings of fullness.
The US Food and Drug Administration (FDA) approved tirzepatide in November 2023 (Zepbound), and the EU followed suit in June 2024 (Mounjaro) for weight management in adults who are obese or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
The results could offer valuable insights into the effectiveness of tirzepatide across various demographics and health backgrounds, potentially paving the way for more personalized treatment strategies and objectives, according to the research team.
